178 related articles for article (PubMed ID: 22760303)
41. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
Wu X; Gu H; Gao Y; Li B; Fan R
Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
[TBL] [Abstract][Full Text] [Related]
42. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
43. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].
Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B
Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839
[TBL] [Abstract][Full Text] [Related]
44. [Outcomes of long-term combined treatment in follicular thyroid carcinoma].
Baranauskas Z; Valuckas KP; Tiskevicius S
Medicina (Kaunas); 2010; 46(4):268-74. PubMed ID: 20571295
[TBL] [Abstract][Full Text] [Related]
45. rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.
Ma C; Tang L; Fu H; Li J; Wang H
Nucl Med Commun; 2013 Dec; 34(12):1150-6. PubMed ID: 24025918
[TBL] [Abstract][Full Text] [Related]
46. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131).
Prpic M; Dabelic N; Stanicic J; Jukic T; Milosevic M; Kusic Z
Ann Nucl Med; 2012 Nov; 26(9):744-51. PubMed ID: 22829399
[TBL] [Abstract][Full Text] [Related]
48. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma.
Kim EY; Kim TY; Kim WG; Yim JH; Han JM; Ryu JS; Hong SJ; Yoon JH; Gong G; Kim WB; Shong YK
Nucl Med Commun; 2011 Oct; 32(10):954-9. PubMed ID: 21849927
[TBL] [Abstract][Full Text] [Related]
49. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.
Bal C; Padhy AK; Jana S; Pant GS; Basu AK
Cancer; 1996 Jun; 77(12):2574-80. PubMed ID: 8640708
[TBL] [Abstract][Full Text] [Related]
50. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.
Ciappuccini R; Hardouin J; Heutte N; Vaur D; Quak E; Rame JP; Blanchard D; de Raucourt D; Bardet S
Eur J Endocrinol; 2014 Aug; 171(2):247-52. PubMed ID: 24866576
[TBL] [Abstract][Full Text] [Related]
51. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
[TBL] [Abstract][Full Text] [Related]
52. Chinese Data of Efficacy of Low- and High-Dose Iodine-131 for the Ablation of Thyroid Remnant.
Ma C; Feng F; Wang S; Fu H; Wu S; Ye Z; Chen S; Wang H
Thyroid; 2017 Jun; 27(6):832-837. PubMed ID: 28401794
[TBL] [Abstract][Full Text] [Related]
53. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Mallick U; Harmer C; Yap B; Wadsley J; Clarke S; Moss L; Nicol A; Clark PM; Farnell K; McCready R; Smellie J; Franklyn JA; John R; Nutting CM; Newbold K; Lemon C; Gerrard G; Abdel-Hamid A; Hardman J; Macias E; Roques T; Whitaker S; Vijayan R; Alvarez P; Beare S; Forsyth S; Kadalayil L; Hackshaw A
N Engl J Med; 2012 May; 366(18):1674-85. PubMed ID: 22551128
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
[TBL] [Abstract][Full Text] [Related]
55. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
56. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.
Chianelli M; Todino V; Graziano FM; Panunzi C; Pace D; Guglielmi R; Signore A; Papini E
Eur J Endocrinol; 2009 Mar; 160(3):431-6. PubMed ID: 19074463
[TBL] [Abstract][Full Text] [Related]
57. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
58. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma.
Czepczyński R; Ziemnicka K; Baczyk M; Oleksa R; Ruchała M; Sowiński J
Thyroid; 2005 Nov; 15(11):1261-5. PubMed ID: 16356090
[TBL] [Abstract][Full Text] [Related]
59. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
[TBL] [Abstract][Full Text] [Related]
60. Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
Forleo R; Fralassi N; Maino F; Capezzone M; Brilli L; Pilli T; Cantara S; Castagna MG
J Endocrinol Invest; 2021 Jan; 44(1):139-144. PubMed ID: 32388842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
